Towards gene therapy for Parkinson's disease

The Lancet Neurology

Volumn 7, Issue 5, 2008, Pages 375-376

  Palfi, Stéphane ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; FLUORINE 18; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; NEUROTROPHIC FACTOR; NEURTURIN; PARVOVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE;

CLINICAL TRIAL; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG MEGADOSE; DYSKINESIA; GENE TRANSFER; HUMAN; LETTER; LOW DRUG DOSE; NERVE DEGENERATION; NEUROSURGERY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; VIRAL GENE THERAPY;

GENE THERAPY; HUMANS; PARKINSON DISEASE;

EID: 41949128614     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70066-8     Document Type: Letter

References (9)

1. Olanow C., Obeso J., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurology 5 (2006) 677-687
2. Kordower J., Emborg M., Bloch J., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
3. Marks W., Ostrem J., Verhagen L., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7 (2008) 400-408
4. Bankiewicz K., Forsayeth J., Eberling J., et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14 (2006) 571-577
5. Kirik D., Georgievska B., Burgeret C., et al. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci U S A 99 (2002) 4708-4713
6. Kaplitt M., Feigin A., Tang C., et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369 (2007) 2097-2105
7. Azzouz M., Martin-Rendon E., Barber R., et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 22 (2002) 10302-10312
8. Jarraya B., Azzouz M., Miskin J., et al. Dopamine production mediated by a tricistronic lentiviral vector reverses motor deficits in a primate model of Parkinson's disease (2004), Society for Neurosciences, San Diego, CA, USA
9. Kordower J., Herzog C., Dass B., et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60 (2006) 706-715